5-fluorouracil + interferon alfa + levamisole

This is a combination regimen consisting of three agents: - **5-fluorouracil (5-FU):** A pyrimidine analog antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis and leading to cell death. It is widely used as an antineoplastic agent in the treatment of colorectal cancer. - **Interferon alfa:** A cytokine with immunomodulatory, antiviral, and antiproliferative properties. In oncology, it can enhance immune responses against tumor cells. - **Levamisole:** Originally developed as an antihelminthic agent but later found to have immunomodulatory effects; it has been used as an adjuvant in chemotherapy regimens for colon cancer. The combination was investigated primarily for adjuvant therapy in stage III colon cancer. However, clinical trials showed that adding levamisole or interferon alfa to 5-FU did not improve survival outcomes and increased toxicity[1]. The use of this triple combination is not standard due to lack of efficacy benefit and higher adverse event rates.

Other names

5-FU + IFN-alpha + levamisole5-fluorouracil plus interferon alfa plus levamisole